Citation Impact
69 standout
Citing Papers
Targeting CDK4 and CDK6 in cancer
2022 Standout
Epidemiology, Staging, and Management of Multiple Myeloma
2021 Standout
Works of Robert Dichmann being referenced
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
2014
A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.
2011
Author Peers
| Author | Oncology | Hematology | Infectious Diseases | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Robert Dichmann | 103 | 52 | 1 | 66 | 9 | 147 | |
| S. Ghosh | 1 | 1 | 2 | 13 | 412 | ||
| Erik Mueggler | 1 | 19 | 167 | ||||
| Ping You | 1 | 7 | 187 | 45 | 457 | ||
| Luca Sarchi | 56 | 2 | 8 | 31 | 386 | ||
| Gábor Besenyei | 130 | 49 | 36 | 562 |
All Works
Loading papers...